Evaluation of imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam and cefepime-zidebactam activities on a wide collection of French clinical Enterobacterales isolates

IF 2.1 4区医学 Q3 INFECTIOUS DISEASES

Diagnostic microbiology and infectious disease Pub Date : 2025-07-15 DOI:10.1016/j.diagmicrobio.2025.117011

Camille Petillon , Mauli Ululuipalelei , Racha Beyrouthy , Simon Proust , Nejla Aissa , Laurent Bret , Nathalie Brieu , Anne Carricajo , Vincent Cattoir , Olivier Dauwalder , Nicolas Degand , Laurent Dortet , Florence Doucet-Populaire , Véronique Dubois , Antoine Grillon , François Guérin , Philippe Lanotte , Nadine Lemaitre , David Leyssene , Catherine Neuwirth , Frédéric Robin

{"title":"Evaluation of imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam and cefepime-zidebactam activities on a wide collection of French clinical Enterobacterales isolates","authors":"Camille Petillon , Mauli Ululuipalelei , Racha Beyrouthy , Simon Proust , Nejla Aissa , Laurent Bret , Nathalie Brieu , Anne Carricajo , Vincent Cattoir , Olivier Dauwalder , Nicolas Degand , Laurent Dortet , Florence Doucet-Populaire , Véronique Dubois , Antoine Grillon , François Guérin , Philippe Lanotte , Nadine Lemaitre , David Leyssene , Catherine Neuwirth , Frédéric Robin","doi":"10.1016/j.diagmicrobio.2025.117011","DOIUrl":null,"url":null,"abstract":"<div><div>In recent years, novel β-lactam-inhibitor combinations (imipenem-relebactam (I/R), meropenem-vaborbactam (M/V), aztreonam-avibactam (A/A)) have been commercialized and some are not yet on the market (cefepime-zidebactam (C/Z)). The objective of this study was to evaluate the efficacy of these β-lactam-β-lactamase inhibitors (BL/BLIs) combinations against a wide collection of French clinical multiresistant <em>Enterobacterales</em> isolates and to assess the performance of the E-test MIC method for I/R and M/V.</div><div>BL/BLIs MICs were determined by broth microdilution on a collection of 200 ESBL-producing and 414 carbapenem-resistant clinical <em>Enterobacterales</em> (<em>K. pneumoniae</em> (271), <em>E. coli</em> (245), <em>E. cloacae complex</em> (48), other <em>species</em> (50)) including 292 carbapenemase-producing isolates. E-test method was evaluated for the determination of I/R and M/V MICs using 131 isolates from this collection.</div><div>All the combinations were active against most ESBL-producing isolates (99-100 %), but C/Z and A/A MIC90 were lower than that of I/R and M/V (2mg/L and 2mg/L <em>versus</em> 8mg/L and 8mg/L). The M/V and I/R E-tests performances were close to those required by the FDA recommendations: Categorical agreement (CA) and Essential agreement (EA) ≥ 90 %, Major discrepancy (MD) and Very major discrepancy (VMD) < 3 %): 96.9 % (CA), 92.4 % (EA), 1.2 % (MD), 6.1 % (VMD) for I/R and 94.7 % (CA), 96.9 % (EA), 4.1 % (MD), 8.8 % (VMD) for M/V.</div><div>This work confirmed the interest of C/Z and A/A combinations against carbapenem-resistant <em>Enterobacterales</em> isolates compared with M/V and I/R. Additionally, the findings indicate that the E-test method can be used for the determination of M/V and I/R MIC for <em>E. coli</em> and <em>K. pneumonia</em>e strains.</div></div>","PeriodicalId":11329,"journal":{"name":"Diagnostic microbiology and infectious disease","volume":"113 3","pages":"Article 117011"},"PeriodicalIF":2.1000,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diagnostic microbiology and infectious disease","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0732889325003347","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

In recent years, novel β-lactam-inhibitor combinations (imipenem-relebactam (I/R), meropenem-vaborbactam (M/V), aztreonam-avibactam (A/A)) have been commercialized and some are not yet on the market (cefepime-zidebactam (C/Z)). The objective of this study was to evaluate the efficacy of these β-lactam-β-lactamase inhibitors (BL/BLIs) combinations against a wide collection of French clinical multiresistant Enterobacterales isolates and to assess the performance of the E-test MIC method for I/R and M/V.

BL/BLIs MICs were determined by broth microdilution on a collection of 200 ESBL-producing and 414 carbapenem-resistant clinical Enterobacterales (K. pneumoniae (271), E. coli (245), E. cloacae complex (48), other species (50)) including 292 carbapenemase-producing isolates. E-test method was evaluated for the determination of I/R and M/V MICs using 131 isolates from this collection.

All the combinations were active against most ESBL-producing isolates (99-100 %), but C/Z and A/A MIC90 were lower than that of I/R and M/V (2mg/L and 2mg/L versus 8mg/L and 8mg/L). The M/V and I/R E-tests performances were close to those required by the FDA recommendations: Categorical agreement (CA) and Essential agreement (EA) ≥ 90 %, Major discrepancy (MD) and Very major discrepancy (VMD) < 3 %): 96.9 % (CA), 92.4 % (EA), 1.2 % (MD), 6.1 % (VMD) for I/R and 94.7 % (CA), 96.9 % (EA), 4.1 % (MD), 8.8 % (VMD) for M/V.

This work confirmed the interest of C/Z and A/A combinations against carbapenem-resistant Enterobacterales isolates compared with M/V and I/R. Additionally, the findings indicate that the E-test method can be used for the determination of M/V and I/R MIC for E. coli and K. pneumoniae strains.

查看原文本刊更多论文

评价亚胺培南-乐巴坦、美罗培南-瓦波巴坦、阿曲那南-阿维巴坦和头孢吡肟-齐德巴坦对法国临床肠杆菌广泛分离株的活性

近年来，新型β-内酰胺抑制剂组合（亚胺培南-勒布巴坦（I/R）、美罗培尼-瓦波巴坦（M/V）、阿曲南-阿维巴坦（A/A））已经商业化，有些尚未上市（头孢吡肟-齐地巴坦（C/Z））。本研究的目的是评估这些β-内酰胺-β-内酰胺酶抑制剂（BL/BLIs）组合对广泛的法国临床多重耐药肠杆菌分离株的疗效，并评估E-test MIC方法对I/R和M/V的性能。采用肉汤微量稀释法测定了200株产esbl和414株耐碳青霉烯临床肠杆菌（271株肺炎克雷伯菌、245株大肠杆菌、48株阴沟肠杆菌复群、50株其他）的BL/BLIs mic，其中292株产碳青霉烯酶菌株。利用该收集的131株分离株，评估了E-test法测定I/R和M/V mic的效果。所有组合对大多数产esbl菌株均有活性（99 ~ 100%），但C/Z和A/A MIC90低于I/R和M/V （2mg/L和2mg/L比8mg/L和8mg/L）。M/V和I/R e测试性能接近FDA建议的要求：分类一致（CA）和基本一致(EA)≥90%，重大差异（MD）和非常重大差异（VMD） <；3%): 96.9% (CA)、92.4% (EA), 1.2% (MD), 6.1% (VMD) I / R和94.7% (CA), 96.9% (EA), 4.1% (MD), 8.8% (VMD) M / V。与M/V和I/R相比，本研究证实了C/Z和A/A组合对碳青霉烯耐药肠杆菌的作用。结果表明，E-test法可用于大肠杆菌和肺炎克雷伯菌的M/V和I/R MIC测定。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diagnostic microbiology and infectious disease 医学-传染病学

CiteScore

5.30

自引率

3.40%

发文量

149

审稿时长

56 days

期刊介绍： Diagnostic Microbiology and Infectious Disease keeps you informed of the latest developments in clinical microbiology and the diagnosis and treatment of infectious diseases. Packed with rigorously peer-reviewed articles and studies in bacteriology, immunology, immunoserology, infectious diseases, mycology, parasitology, and virology, the journal examines new procedures, unusual cases, controversial issues, and important new literature. Diagnostic Microbiology and Infectious Disease distinguished independent editorial board, consisting of experts from many medical specialties, ensures you extensive and authoritative coverage.